Table 2.

Oligonucleotides used for amplification of human miRNAs and target gene binding sites

Gene#	Forward Primer (5′-3′)	Reverse Primer (5′-3′)
miR-96	TACCGAAGGGCCATAAACAG	AGGCAGTGTAAGGCGATCTG
miR-182	AGCAGGAAGGGGGACTGT	GCAGGGAAACACAGAGTGTCA
miR-183	AAGGTCATCTTGGGCTGATG	GGCTCTCTGGGGACACACT
AQP5	TGGCTGCACAGTTAGAGAGG	CGGCATTCAATGAACCAGTC
ATP2B4	TCCTTGGTAGTCACTTGTCATTTT	TCACACTACTGGCGGATTTT
BTG1	TCTTGGGGATGGATTATGGA	TCTGGGAGAAACTGAAACCA
CaBP1	CAGGATGTACTGGCGGATG	GACATGCTGTGTGGGGTCT
Cav1.2 (96)	CAAGAAGGCATTTTGCTTCA	AAAGCTTGTCACACTCCAAATACA
Cav1.2 (182)	TTGACAGCATGTTGCAGTTTC	TTGGGCATACACAATGGTTG
Cav1	TGCATCAGCCGTGTCTATTC	TCAGACTGCCAAAAATAGATGAA
CELSR1	CTGCCCTTGAAGTGGAGTG	CCCTCTCAGTTCTGGCTTTG
CELSR2	CCTGCTCCTGTCTTGTGCTT	GGGAGTCAATTTCCAGCGTA
EZRIN	GAAACTTCATGCTGGCCTGT	CTGTGTGTGCGAGAGTGCTT
GNG5	TTCCCAAACCACTCCTTATGA	ATTGTATGCTGCTGCCAGTG
GRID1	TTCCCAATTTTCGAAGTCAG	GGTTCCTCGTCTTCCCTTCT
KCC2	GGTTGCAAACCAAATCAAGAG	ATTTTGTGCAGACGGGAGTC
KCNJ14	GTAGAGCACCCAGCCAAGAG	CCTTTTGGCATTACAGAACCA
MITF (96)	TTGGACTAGCACTGACTGAACTG	AGCATCACCAATGTTTCCAAG
MITF (182)	ATTTCTGCAGGTGGCAGGT	TTCCTTTGTGCTTTTAACTTCCTA
MYRIP (96)	TTGACAAAAATGTGTACTGTGTAAGC	GATCAAAATCACTTGATGACAAAA
MYRIP (182)	AAGTGCCTGCTCTGAAGGAG	GGAAATGCACATAGCAGCAA
MYRIP (182)	CAAGTGATTTTGATCTTTAGTGTCA	ATCTTGGCCCCTCCAGTTAC
NCS1	TTGCCATCTATCGACCTTCC	CAGGACAGGGGAGAGGAGAG
NEFL	CAGATGCAAGCTATGTGCAA	GTTAAAAGGGGCACTGACCA
PEX19	CAGCTATGGGGAACATCTGG	GGCAGAAACCACAATGGAGT
PPP2CA	CCTAATGGAAATGGGAAGAGC	TCCAATGATTGTTTGCTGCT
RDX	AGCTGAACCACCAACAGAGAA	TGGAAAAGAGGCAATGGAAC
RYK	TTGGACTAGGGGTACATTCTTACA	CAAGGCAGACCAGGTATCTTTT
SLC6A6	GATCAAGGGCCTTATGTGGA	TGTGAAAATTCTGCGGTCTG
TFCP2L3 (96)	GCCATGTGAGAGCTGTGAAC	GCATGTAGCAGGAGACCACA
TFCP2L3 (96)	GCCCTAAGGCAGAAGATGAA	TGTTTCGCTCAGGAAATTTTG
TFCP2L3 (96)	GCCCAGAAACTTAGGAAGCA	GATTCCCCCTCTCCCATTTA
TREK-1	GCTTGTTGAACGGTCCACTT	TGGTCCATATCTAGGCTCAGTT
ZCCHC3	GTCCCAAAGCAGTGCACAAT	TTTTAAAAGGGAGGGGCAAC

^#Round brackets: miRNA binding site